摘要
2013年ACCF/AHA对ST段抬高性心肌梗死(STEMI)治疗指南更新有一些亮点,提出首次医疗接触(FMC)到再灌注的救治时间,使得心肌梗死的救治由"院内急救"提前到"院前急救";首次引入"door‐in‐door-out(DIDO)时间"概念,强调患者迅速转运PCI;强调了新型抗血小板P2Y12受体抑制剂普拉格雷和替格瑞洛的抗栓地位及合理应用,为急性心肌梗死的救治提供了最新依据。
Recently,ACCF/AHA constantly updated with acute coronary syndrome（ACS）treatment guidelines according to large-scale clinical trials,and published the new 2013guideline for the management of STEMI last year,which had a lot of bright spots,such as proposed ＂first medical contact（FMC）to device time＂,advanced treatment of STEMI from ＂hospital emergency＂ to ＂pre-hospital care＂;introduced the conception of ＂doorin-door-out（DIDO）time＂ firstly,emphasized the rapid transfer of patients at a non-PCI-capable hospital and the antithrombotic position of the new anti-platelet P2Y12receptor inhibitors prasugrel and ticagrelor,etc.We believe this guideline will provide the latest evidences for the management of STEMI in our clinical practice.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2014年第5期369-371,共3页
Journal of Clinical Cardiology
关键词
美国心脏病学基金会
美国心脏协会
急性ST段抬高性心肌梗死
指南
American College of Cardiology Foundation（ACCF）
American Heart Association（AHA）
ST-el-evation myocardial infarction
guideline
